financetom
Business
financetom
/
Business
/
Trip.com Shares Slide After Travel Service Provider Misses Q1 Earnings Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Trip.com Shares Slide After Travel Service Provider Misses Q1 Earnings Estimates
May 26, 2025 10:34 AM

Trip.com Group Ltd ( TCOM ) reported unaudited results for the first quarter after the market close on Monday. Here’s a rundown of the report.

Q1 Earnings: Trip.com ( TCOM ) reported first-quarter revenue of $1.91 billion, in line with analyst estimates, according to Benzinga Pro. The travel service provider reported first-quarter adjusted earnings per ADS of 82 cents, missing estimates of 86 cents.

Total revenue was up 16% year-over-year. Here’s a breakdown of revenue growth by category:

Accommodation reservation revenue: up 23%

Transportation ticketing revenue: up 8%

Packaged-tour revenue: up 7%

Corporate travel revenue: up 12%

Trip.com ( TCOM ) ended the first quarter with $12.8 billion in cash, cash equivalents, restricted cash and short-term investments.

“We are pleased to see a strong start to 2025. As travel becomes an increasingly integral part of everyday life, we remain committed to meeting the evolving needs of travelers through innovative, localized and customer-centric solutions. This positions us well to sustain growth momentum and deliver lasting value to our customers, partners, and shareholders,” said Jane Sun, CEO of Trip.com ( TCOM )

Trip.com’s management team will further discuss the quarter on a conference call with investors and analysts at 8 p.m. ET. The company also scheduled a shareholder meeting for June 30.

TCOM Price Action: Trip.com ( TCOM ) shares were down about 2% year-to-date heading into the print. The stock was down 1.79% after-hours, trading at $65.90 at the time of publication Monday, according to Benzinga Pro.

Read Next:

Airbnb CEO Brian Chesky Reveals Why He Doesn’t Do Emails And Early Morning Meetings, Says Silicon-Valley Founders Don’t Need To Be ‘Miserable’

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dyne Therapeutics Q4 Net Loss Narrows; Shares Rise
Dyne Therapeutics Q4 Net Loss Narrows; Shares Rise
Feb 27, 2025
09:41 AM EST, 02/27/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) shares were up 1.7% in early trading Thursday after the company reported a Q4 net loss of $0.88 per diluted share, compared with a $1.09 loss a year earlier. Analysts polled by FactSet expected a $0.94 loss. The company did not report revenue for the quarter ended Dec....
US House panel subpoenas tech giants over foreign communications
US House panel subpoenas tech giants over foreign communications
Feb 27, 2025
WASHINGTON, Feb 27 (Reuters) - The U.S. House Judiciary Committee has subpoenaed eight major technology companies, including Alphabet, Meta, Apple ( AAPL ) and X Corp, seeking details about their communications with other countries regarding compliance with laws impacting speech, it said on Thursday. House Judiciary Committee Chairman Jim Jordan, a Republican, sent the subpoenas on Wednesday and also included...
NCR Voyix Posts Q4 Adjusted Earnings Above Analysts Estimates; Revenue Falls; 2025 Guidance Set
NCR Voyix Posts Q4 Adjusted Earnings Above Analysts Estimates; Revenue Falls; 2025 Guidance Set
Feb 27, 2025
09:35 AM EST, 02/27/2025 (MT Newswires) -- NCR Voyix ( VYX ) reported Q4 non-GAAP earnings Thursday of $0.22 per diluted share. The year-earlier figure was not provided. Analysts polled by FactSet expected $0.11 per share. Revenue for the quarter ended Dec. 31 was $682 million, down from $796 million a year earlier. No comparable revenue estimates were available. NCR...
Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls
Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls
Feb 27, 2025
08:53 AM EST, 02/27/2025 (MT Newswires) -- Kymera Therapeutics ( KYMR ) reported a Q4 net loss Thursday of $0.88 per diluted share, wider than the loss of $0.25 a year earlier. Analysts polled by FactSet expected a loss of $0.86. Collaboration revenue for the quarter ended Dec. 31 was $7.4 million, down from $47.9 million a year earlier. Analysts...
Copyright 2023-2026 - www.financetom.com All Rights Reserved